These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18232649)

  • 21. Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure.
    Jansa J; Jorda R; Škerlová J; Pachl P; Peřina M; Řezníčková E; Heger T; Gucký T; Řezáčová P; Lyčka A; Kryštof V
    Eur J Med Chem; 2021 Apr; 216():113309. PubMed ID: 33711765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and evaluation of 3,5-disubstituted 7-azaindoles as Trk inhibitors with anticancer and antiangiogenic activities.
    Hong S; Kim J; Seo JH; Jung KH; Hong SS; Hong S
    J Med Chem; 2012 Jun; 55(11):5337-49. PubMed ID: 22575050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.
    Hu X; Zhao H; Wang Y; Liu Z; Feng B; Tang C
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3385-3390. PubMed ID: 30197029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors.
    Lee J; Kim KH; Jeong S
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4203-5. PubMed ID: 21684737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs).
    Schmitt L; Hoppe J; Cea-Medina P; Bruch PM; Krings KS; Lechtenberg I; Drießen D; Peter C; Bhatia S; Dietrich S; Stork B; Fritz G; Gohlke H; Müller TJJ; Wesselborg S
    Cell Death Discov; 2024 Jun; 10(1):279. PubMed ID: 38862521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
    Gaisina IN; Gallier F; Ougolkov AV; Kim KH; Kurome T; Guo S; Holzle D; Luchini DN; Blond SY; Billadeau DD; Kozikowski AP
    J Med Chem; 2009 Apr; 52(7):1853-63. PubMed ID: 19338355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and cytotoxic evaluation of new derivatives of the marine alkaloid variolin B.
    Fresneda PM; Delgado S; Francesch A; Manzanares I; Cuevas C; Molina P
    J Med Chem; 2006 Feb; 49(3):1217-21. PubMed ID: 16451088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.
    Pevarello P; Brasca MG; Amici R; Orsini P; Traquandi G; Corti L; Piutti C; Sansonna P; Villa M; Pierce BS; Pulici M; Giordano P; Martina K; Fritzen EL; Nugent RA; Casale E; Cameron A; Ciomei M; Roletto F; Isacchi A; Fogliatto G; Pesenti E; Pastori W; Marsiglio A; Leach KL; Clare PM; Fiorentini F; Varasi M; Vulpetti A; Warpehoski MA
    J Med Chem; 2004 Jun; 47(13):3367-80. PubMed ID: 15189033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
    Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
    Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.
    Pevarello P; Fancelli D; Vulpetti A; Amici R; Villa M; Pittalà V; Vianello P; Cameron A; Ciomei M; Mercurio C; Bischoff JR; Roletto F; Varasi M; Brasca MG
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1084-90. PubMed ID: 16290148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.
    Bramson HN; Corona J; Davis ST; Dickerson SH; Edelstein M; Frye SV; Gampe RT; Harris PA; Hassell A; Holmes WD; Hunter RN; Lackey KE; Lovejoy B; Luzzio MJ; Montana V; Rocque WJ; Rusnak D; Shewchuk L; Veal JM; Walker DH; Kuyper LF
    J Med Chem; 2001 Dec; 44(25):4339-58. PubMed ID: 11728181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.
    Czudor Z; Balogh M; Bánhegyi P; Boros S; Breza N; Dobos J; Fábián M; Horváth Z; Illyés E; Markó P; Sipos A; Szántai-Kis C; Szokol B; Őrfi L
    Bioorg Med Chem Lett; 2018 Feb; 28(4):769-773. PubMed ID: 29329658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.
    Shao H; Foley DW; Huang S; Abbas AY; Lam F; Gershkovich P; Bradshaw TD; Pepper C; Fischer PM; Wang S
    Eur J Med Chem; 2021 Mar; 214():113244. PubMed ID: 33581551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.
    VanderWel SN; Harvey PJ; McNamara DJ; Repine JT; Keller PR; Quin J; Booth RJ; Elliott WL; Dobrusin EM; Fry DW; Toogood PL
    J Med Chem; 2005 Apr; 48(7):2371-87. PubMed ID: 15801830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.
    Huang S; Li R; Connolly PJ; Emanuel S; Middleton SA
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4818-21. PubMed ID: 16870444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK).
    Axten JM; Medina JR; Feng Y; Shu A; Romeril SP; Grant SW; Li WH; Heerding DA; Minthorn E; Mencken T; Atkins C; Liu Q; Rabindran S; Kumar R; Hong X; Goetz A; Stanley T; Taylor JD; Sigethy SD; Tomberlin GH; Hassell AM; Kahler KM; Shewchuk LM; Gampe RT
    J Med Chem; 2012 Aug; 55(16):7193-207. PubMed ID: 22827572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents.
    Huang XF; Lu X; Zhang Y; Song GQ; He QL; Li QS; Yang XH; Wei Y; Zhu HL
    Bioorg Med Chem; 2012 Aug; 20(16):4895-900. PubMed ID: 22819191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors.
    Al-awar RS; Ray JE; Hecker KA; Joseph S; Huang J; Shih C; Brooks HB; Spencer CD; Watkins SA; Schultz RM; Considine EL; Faul MM; Sullivan KA; Kolis SP; Carr MA; Zhang F
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3925-8. PubMed ID: 15225699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and evaluation of functionalized isoindigos as antiproliferative agents.
    Wee XK; Yeo WK; Zhang B; Tan VB; Lim KM; Tay TE; Go ML
    Bioorg Med Chem; 2009 Nov; 17(21):7562-71. PubMed ID: 19783149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones.
    Beckers T; Sellmer A; Eichhorn E; Pongratz H; Schächtele C; Totzke F; Kelter G; Krumbach R; Fiebig HH; Böhmer FD; Mahboobi S
    Bioorg Med Chem; 2012 Jan; 20(1):125-36. PubMed ID: 22169601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.